Abstract
Background
Few studies have been conducted to assess the ambulatory blood pressure (ABP) in IgA nephropathy (IgAN) patients. This study aimed to determine the relationships between ABP and renal histopathological findings assessed using the Oxford classification (OC) and the Japanese classification (JC), which have recently established histopathological criteria for IgAN.
Methods
This cross-sectional study included biopsy-diagnosed IgAN patients, in whom both a renal biopsy and ABP measurement were performed. The histopathological findings were assessed using the OC and the JC and were analyzed in relation to the ABP.
Results
A total of 111 IgAN patients were included. The score of interstitial fibrosis and tubular atrophy (T score) using the OC was a significantly associated factor with both the daytime and nighttime ABP values. In contrast, the other histopathological scores, including mesangial hypercellularity, endocapillary hypercellularity and segmental glomerulosclerosis, did not show significant associations with the ABP. The histological grade (H-grade) using the JC, which was based on the sum of injured glomeruli, was associated with the daytime ABP, but not with the nighttime ABP. The associations between the T score using the OC (%) and the daytime and nighttime ABP values were independent of age, gender, renal function, proteinuria and the use of antihypertensive medications, whereas the H-grade using the JC (%) did not show significant associations after adjusting for these clinical parameters.
Conclusions
These results suggest that the T score using the OC is the most relevant renal histopathological parameter associated with abnormalities of circadian blood pressure in IgAN patients.
Keywords: Oxford classification, IgA nephropathy, ambulatory blood pressure, tubulointerstitial fibrosis, renal biopsy
Introduction
IgA nephropathy (IgAN) is the most frequently occurring primary glomerulonephritis and is the most common cause of CKD and end-stage kidney disease (ESKD) worldwide [1]. Recent studies have shown that ∼35–50% of these patients progress to ESKD within 30 years despite treatments [2, 3].
The Oxford classification (OC) recently established pathological criteria for prediction of the renal prognosis in IgAN patients [4, 5]. The OC identified mesangial proliferation, endocapillary proliferation, segmental glomerulosclerosis and interstitial fibrosis and tubular atrophy (IF/TA) to be independent predictors of renal outcome. Many studies have confirmed the prognostic importance of these histological findings, especially IF/TA, regarding the various degrees of disease severity and race of IgAN patients [6–8]. The Japanese classification (JC) was also proposed to predict the progression to ESKD in IgAN patients [9]. In this classification system, the histological grade (H-grade) identified glomerular lesions, including global and segmental glomerulosclerosis, and extracapillary lesions to be prognostic factors. However, the H-grade does not include IF/TA since the severity of global glomerulosclerosis strongly correlated with the severity of IF/TA. These histological classifications are still being validated for their ability to predict renal prognosis of IgAN patients.
Accumulating evidence has suggested that the measurement of ambulatory blood pressure (ABP) is essential for the diagnosis of hypertension and the evaluation of optimal antihypertensive treatment in CKD patients [10]. ABP monitoring is especially useful for detecting circadian or occasional abnormal blood pressure, such as nocturnal hypertension and white-coat or masked hypertension. Nocturnal hypertension is frequently observed in CKD patients [11]. A subgroup analysis of the CKD-JAC study revealed that the prevalence of masked hypertension was 30.9% in CKD stage G3–5 patients [12]. Of particular importance, these abnormal patterns of blood pressure were shown to be strongly associated with renal and cardiovascular outcomes [13, 14]. In patients with IgAN, hypertensive status has been reported to be one of the important predictors for renal outcome [15, 16]. However, only a few studies have assessed ABP in these patients. In addition, the relationships between ABP and histopathological findings that are able to stratify the risk for renal progression in IgAN patients have not yet been elucidated. By using the OC and the JC, we therefore aimed to determine the histopathological findings that are relevantly associated with ABP abnormalities in IgAN patients.
Materials and methods
Settings and participants
This retrospective cross-sectional study included consecutive patients who underwent percutaneous native renal biopsies and ABP monitoring at the Jikei University Hospital, Tokyo, Japan, during the period from April 2010 to March 2014. The indications for renal biopsy were persistent proteinuria and/or elevated serum creatinine levels. The histopathological diagnosis of IgAN was made by the confirmation of focal or diffuse mesangial proliferation together with predominant deposition of IgA in the mesangial area. The exclusion criteria included (i) patients with Henoch–Schönlein purpura, systemic lupus erythematosus and liver cirrhosis; (ii) patients who have a pathological diagnosis with other renal or systemic diseases and (iii) a biopsy specimen containing less than eight glomeruli. Both the renal biopsies and ABP monitoring were performed during the same hospitalization period. The patients consumed a diet including 6 g/day of sodium chloride during the hospitalization. All patients included in this study provided their written informed consent for the renal biopsy. The study protocol was approved by the ethics review board of the Jikei University School of Medicine [no. 26–168 (7673)].
Clinical variables
The clinical information was obtained from the data collected during the hospitalization period. Diabetes mellitus was defined as an HbA1c value ≥6.5% (NGSP) or as patients under medical treatment for diabetes mellitus at the time of a renal biopsy. Hyperuricemia was defined as a uric acid value ≥7 mg/dL or as patients receiving antihyperuricemic medications regardless of gender. The eGFR was calculated by applying a modified three-variable equation for estimating the GFR for Japanese patients [17]: eGFR = 194 × age−0.287 × sCr−1.094 (× 0.739, if female), where sCr is the serum creatinine level. The amount of urinary protein excretion was measured by a 24-h urinary collection.
Measurement of ABP
ABP measurement was planned in all patients who underwent a renal biopsy, regardless of the presence of hypertension when blood pressure is measured during a visit to the doctor's office, to detect any masked hypertension and evaluate the possible risk for renal progression. The ABP monitoring analyses were performed ∼4–7 days after admission using a TM-2431C device (A&D, Tokyo, Japan). We defined the ABP parameters as follows: (i) daytime and nighttime ABP were defined as the average of daytime and nighttime mean ABP, respectively, and (ii) the night: day ratio (NDR) was defined as the ratio of the nighttime ABP to daytime ABP [18].
Histopathological analysis
All renal tissue specimens were obtained via percutaneous needle biopsies. The patients' information was blinded at the time of the histopathological evaluation.
The histopathological grading was performed according to the definitions of the OC of IgAN [4, 5]. The definition of the clinical grade (C-grade) and H-grade according to the JC are shown in Supplementary Table S1. The C-grade according to the JC was defined based on the value of the eGFR and the amount of urinary protein excretion. The ratio of prognostic glomeruli (PG) was defined as follows [19]: (number of glomeruli with global and segmental scleroses, or extracapillary lesions/number of total obtained glomeruli × 100 (%)). The H-grade according to the JC was defined based on the PG as follows: H-grade I 0–24.9%, H-grade II 25–49.9%, H-grade III 50–74.9%, and H-grade IV ≥75%.
Statistical analysis
Data are presented as the mean ± SD. For comparisons between two groups, Student's t-test or the Mann–Whitney U-test was used as appropriate. Differences between three groups were analyzed by a one-way analysis of variance (ANOVA) or the Kruskal–Wallis test as appropriate. The Tukey–Kramer test was used to determine which group caused the difference. Linear regression analyses for both the daytime and nighttime ABP were performed using the forced entry method to determine the effect of histopathological lesions on the ABP. The adjustment variables were those considered to be clinically relevant. Data were analyzed using a commercially available software program (SPSS, Chicago, IL) and P-values <0.05 were considered to be significant in all statistical tests.
Results
Clinicopathological characteristics of patients with IgAN at the time of biopsy
We initially enrolled 128 consecutive patients with biopsy-diagnosed IgAN. Patients were excluded if they had an inadequate renal biopsy specimen of fewer than eight glomeruli (n = 4). Among the remaining 124 patients, the ABP value in 111 patients (90%) was measured. The clinicopathological characteristics of the 13 patients who did not receive ABP monitoring were comparable to the 111 patients included in this study (data not shown). The clinicopathological characteristics of the IgAN patients at the time of biopsy are summarized in Table 1. Approximately half of these patients were not taking antihypertensive medications. Sixty-four (58%) of these patients were those with preserved renal functions (eGFR ≥60 mL/min/1.73 m2). Sixteen (14%) and 45 (41%) of these patients were hypertensive according to the office blood pressure (≥140/90 mmHg) and ABP (≥130/80 mmHg), respectively [20]. Thirty-two (29%) and three (3%) patients showed masked (normotensive by office blood pressure and hypertensive by ABP) and white-coat (hypertensive by office blood pressure and normotensive by ABP) hypertension, respectively. The distribution of the histopathological findings was comparable to those of previously reported large IgAN patient cohorts [5, 6].
Table 1.
Clinicopathological characteristics of patients with IgAN at the time of biopsy
| Clinical findings | |
|---|---|
| Age, years | 40 ± 13 (15–70) |
| Male, n (%) | 73 (66) |
| BMI, kg/m2 | 22.6 ± 3.5 |
| Current smoker, n (%) | 16 (14) |
| No. of antihypertensive medications, n (%) | 0.8 ± 1.0 |
| 0 | 61 (55) |
| 1 | 20 (18) |
| 2 | 19 (17) |
| 3 | 11 (10) |
| ACE-I/ARB, n (%) | 37 (33) |
| Diuretics, n (%) | 2 (2) |
| Corticosteroids, n (%) | 5 (5) |
| Diabetes mellitus, n (%) | 3 (3) |
| Hyperuricemia, n (%) | 54 (49) |
| Urinary protein excretion, g/day | 1.2 ± 1.8 (0.1–7.7) |
| eGFR, mL/min/1.73 m2 | 64 ± 26 (11–121) |
| GFR stage, n (%) | |
| G1 | 17 (15) |
| G2 | 47 (42) |
| G3a | 19 (17) |
| G3b | 13 (12) |
| G4, 5 | 15 (14) |
| Office blood pressure, mmHg | 122/73 |
| 24-h ABP, mmHg | 119/77 |
| Daytime ABP, mmHg | 121/79 |
| Nighttime ABP, mmHg | 111/70 |
| NDR of ABP | 0.90 |
| Histopathological findings, n (%) | |
| M1 | 35 (32) |
| E1 | 30 (27) |
| S1 | 83 (75) |
| T1/T2 | 20/17 (18/15) |
| Global glomerulosclerosis, % | 22 ± 21 |
| Segmental glomerulosclerosis, % | 7 ± 8 |
| Crescentic lesion present, n (%) | 66 (59) |
| Cellular/fibrocellular/fibrous, n (%) | 19(17)/51(46)/38(34) |
| PG, % | 35 ± 23 |
| H-grade I, n (%) | 48 (43) |
| H-grade II, n (%) | 32 (29) |
| H-grade III + IV, n (%) | 31 (28) |
Values are given as the mean ± SD (range) unless otherwise indicated.
BMI, body mass index; ACE-I, angiotensinogen-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; PG, the ratio of prognostic glomeruli to total obtained glomeruli according to the JC.
Comparison of the ABP according to the histopathological findings using the Oxford classification
The relationships between the ABP and the histopathological findings using the OC in all patients (n = 111) are shown in Table 2. There were no significant differences in the daytime and nighttime ABP values between M0 versus M1, E0 versus E1 and S0 versus S1. In contrast, the daytime and nighttime ABP values were significantly different among the three groups according to the T score (one-way ANOVA). There was a significant difference between T0 versus T2 according to a post hoc analysis in both the daytime and nighttime ABP. Moreover, patients with more severe T scores tended to demonstrate a higher ABP. The subgroup analyses of the patients not taking antihypertensive medications (n = 61), patients without advanced renal function decline (eGFR >30 mL/min/1.73 m2; n = 96), patients with renal function decline (eGFR <60 mL/min/1.73 m2; n = 45) and patients with overt proteinuria (urinary protein excretion >0.5 g/day; n = 77) are given in Supplementary Tables S2–S5. As well as in the analysis in all patients, patients with more severe T scores tended to demonstrate a higher ABP in these subgroup analyses, although the nighttime ABP value between T0 versus T1 and T2 in the patients not taking antihypertensive medications and the ABP value among T scores in the patients with renal function decline and those with overt proteinuria did not reach statistical significance.
Table 2.
Comparison of the mean value and NDR of ABP according to the Oxford classification (n = 111)
| M0 (n = 76) | M1 (n = 35) | P-value | ||
| Daytime mean ABP | 93 ± 10 | 92 ± 12 | 0.727 | |
| Nighttime mean ABP | 84 ± 12 | 83 ± 13 | 0.648 | |
| NDR | 0.90 ± 0.08 | 0.90 ± 0.06 | 0.680 | |
| E0 (n = 81) | E1 (n = 30) | |||
| Daytime mean ABP | 93 ± 11 | 93 ± 10 | 0.861 | |
| Nighttime mean ABP | 84 ± 13 | 84 ± 11 | 0.841 | |
| NDR | 0.90 ± 0.07 | 0.90 ± 0.07 | 0.840 | |
| S0 (n = 28) | S1 (n = 83) | |||
| Daytime mean ABP | 94 ± 11 | 92 ± 10 | 0.597 | |
| Nighttime mean ABP | 85 ± 15 | 83 ± 12 | 0.636 | |
| NDR | 0.90 ± 0.07 | 0.90 ± 0.07 | 0.952 | |
| T0 (n = 74) | T1 (n = 20) | T2 (n = 17) | ||
| Daytime mean ABP | 91 ± 9 | 95 ± 10 | 98 ± 15a | 0.012 |
| Nighttime mean ABP | 82 ± 11 | 85 ± 12 | 92 ± 16a | 0.010 |
| NDR | 0.90 ± 0.07 | 0.89 ± 0.08 | 0.93 ± 0.07 | 0.210 |
| AA0 (n = 26) | AA1 (n = 56) | AA2 (n = 29) | ||
| Daytime mean ABP | 90 ± 10 | 93 ± 9 | 95 ± 13 | 0.240 |
| Nighttime mean ABP | 79 ± 11 | 84 ± 11 | 87 ± 16 | 0.052 |
| NDR | 0.88 ± 0.06 | 0.91 ± 0.07 | 0.92 ± 0.08 | 0.111 |
| AO0 (n = 25) | AO1 (n = 43) | AO2 (n = 42) | ||
| Daytime mean ABP | 89 ± 8 | 93 ± 12 | 95 ± 10 | 0.048 |
| Nighttime mean ABP | 81 ± 8 | 82 ± 14 | 88 ± 12 | 0.049 |
| NDR | 0.91 ± 0.04 | 0.89 ± 0.07 | 0.92 ± 0.08 | 0.129 |
Values are shown as the mean ± SD.
AA, arterial lesions; AO, arteriole lesions. aSignificant difference versus T0 using the Tukey–Kramer test.
There were weak but significant relationships between the arteriole lesion scores and both the daytime and nighttime ABP values in the analyses in all patients, but not in the subgroup analyses of the patients not taking antihypertensive medications. No significant histopathological parameter was found to be associated with the NDR.
Comparison of ABP according to grading by the Japanese classification
The relationships between ABP and the C- and H-grades using the JC in the analyses of all patients (n = 111) are given in Table 3. Overall, the daytime ABP was significantly different among the patients categorized according to the H-grade using the JC, whereas the nighttime ABP was not. There were no significant relationships in either the daytime or nighttime ABP in the subgroup analysis of the patients not taking antihypertensive medications (Supplementary Table S2). In contrast, the C-grade using the JC was strongly associated with both the daytime and nighttime ABP values in the analyses of all patients and the patients not taking antihypertensive medications.
Table 3.
Comparison of the mean value and NDR of ABP according to the Japanese classification (n = 111)
| C-grade I (n = 34) | C-grade II (n = 39) | C-grade III (n = 38) | P-value | |
| Daytime mean ABP | 88 ± 7 | 93 ± 9 | 96 ± 12a | 0.002 |
| Nighttime mean ABP | 79 ± 10 | 83 ± 11 | 88 ± 14a | 0.004 |
| NDR | 0.89 ± 0.08 | 0.90 ± 0.06 | 0.91 ± 0.08 | 0.470 |
| H-grade I (n = 48) | H-grade II (n = 32) | H-grade III/IV (n = 31) | ||
| Daytime mean ABP | 90 ± 9 | 92 ± 9 | 97 ± 13a | 0.021 |
| Nighttime mean ABP | 81 ± 11 | 84 ± 10 | 88 ± 15 | 0.087 |
| NDR | 0.90 ± 0.07 | 0.91 ± 0.07 | 0.90 ± 0.08 | 0.936 |
Values are shown as the mean ± SD.
aSignificant difference versus Grade I using the Tukey–Kramer test.
Multiple linear regression analyses of the daytime and nighttime ABP values
To compare the influences of the severity of IF/TA according to the OC and the PG according to the JC on blood pressure, we performed multiple linear regression analyses for the daytime and nighttime ABP values (Table 4). The severity of IF/TA (%) and the PG (%) were significantly associated with both the daytime and nighttime ABP values according to the univariate analyses (Model 1). The severity of IF/TA was a significant factor associated with both the daytime and nighttime ABP, independent of age, gender, eGFR, proteinuria and the use of antihypertensive medications (Models 2–5). In contrast, the PG was not a significant parameter associated with the daytime or nighttime ABP after adjusting for these clinical variables (Models 3–5).
Table 4.
Multiple linear regression analyses for the daytime and nighttime ABP values
| IF/TA |
PG |
|||
|---|---|---|---|---|
| Standardized β | P-value | Standardized β | P-value | |
| Daytime ABP | ||||
| Model 1 | 0.338 | <0.001 | 0.275 | 0.004 |
| Model 2 | 0.312 | 0.001 | 0.252 | 0.009 |
| Model 3 | 0.284 | 0.047 | 0.139 | 0.300 |
| Model 4 | 0.321 | 0.022 | 0.177 | 0.173 |
| Model 5 | 0.329 | 0.024 | 0.176 | 0.180 |
| Nighttime ABP | ||||
| Model 1 | 0.318 | 0.001 | 0.242 | 0.011 |
| Model 2 | 0.263 | 0.006 | 0.181 | 0.064 |
| Model 3 | 0.242 | 0.092 | 0.072 | 0.533 |
| Model 4 | 0.294 | 0.040 | 0.110 | 0.408 |
| Model 5 | 0.313 | 0.035 | 0.110 | 0.411 |
Model 1 was unadjusted; Model 2 was adjusted for age and gender; Model 3 was adjusted for the eGFR and amount of urinary protein excretion; Model 4 was adjusted for covariates in Models 2 and 3; Model 5 was adjusted for covariates in Model 4 plus the use of antihypertensive medications (versus no medication). PG, the ratio of prognostic glomeruli to total obtained glomeruli according to the JC.
Discussion
This cross-sectional study showed that the T score using the OC was closely correlated with both the daytime and nighttime ABP, whereas the other histopathological scores were not in IgAN patients. The H-grade using the JC, which is based on the sum of the glomerular lesions, was associated with daytime ABP, but not nighttime ABP (Tables 2 and 3). Almost similar trends were observed in the subgroup analyses of the patients with and without severe disease involvement, including renal function decline or overt proteinuria (Supplementary Tables S3–S5). In the multiple linear regression analyses, the T score according to the OC was significantly associated with both the daytime and nighttime ABP, independent of important clinical variables, including age, gender, eGFR, proteinuria and the use of antihypertensive medications. In contrast, the PG (%) using the JC was not significantly associated with the ABP after an adjustment for these variables (Table 4).
It is well accepted that IF/TA is a feature of the final common pathway in advanced renal disease and the most precise predictor for the renal prognosis in several types of progressive renal diseases, including IgAN [21–23]. Importantly, our current study showed that the severity of IF/TA was significantly associated with ABP independent of the renal disease involvement, suggesting that the association between ABP and IF/TA is not simply the result of renal impairment, and these correlations might occur in an earlier stage of renal disease. In support of this idea, significant relationships between the salt-sensitivity index and the severity of IF/TA in normotensive IgAN patients with preserved renal function were reported [24]. In addition, an epidemiological study from Japan showed a significant positive correlation between the casual blood pressure and the urinary beta-2 microglobulin:creatinine ratio (which reflects the severity of tubulointerstitial damage) in the general population without an apparent renal function decline [25].
Consistent with our current results, previous studies have suggested that tubulointerstitial mechanisms directly mediate abnormalities in blood pressure. Johnson et al. [26] hypothesized that renal interstitial inflammatory and tubular changes play a critical part in inducing salt-sensitive hypertension. They demonstrated that exogenous IF/TA using protein overload or cellophane wrapping (pressure injury) of the kidney in experimental rat models could cause salt-sensitive hypertension [27, 28]. More recently, several possible mechanisms underlying hypertension induced by the tubulointerstitium have been proposed, such as angiotensin II and its receptor axis [29, 30], including angiotensin II type1 receptor-associated protein [31, 32], dopamine [33, 34] and endothelin-1 [35]. The results of these experimental studies support the hypothesis that blood pressure could be, at least in part, regulated by the renal tubulointerstitium.
It is difficult to compare directly the superiority of the OC with that of the JC. Since the OC applies a split system, it is useful to simply describe the predictive value of each histopathological grade in IgAN. Our current results may therefore add valuable meaning to the T score using the OC regarding its relationship with circadian blood pressure abnormalities in IgAN patients. In contrast, the JC uses a lumped system consisting of the C-grade, based on the eGFR value and proteinuria, and the H-grade, based on the PG. In this study, the C-grade using the JC was well correlated with both the daytime and nighttime ABP. These results suggested that the C-grade may compensate for the blood pressure effect on the renal prognosis of IgAN. Indeed, Okonogi et al. [36] showed that risk stratification using only eGFR values and the amount of urinary protein excretion could predict the long-term renal outcome in IgAN patients. However, whether ABP monitoring is superior to the office blood pressure measurement and stratification according to eGFR and proteinuria for predicting renal outcome in IgAN patients must be confirmed.
The arteriole (AO) grade exhibited significant associations with the daytime and nighttime ABP in the patients overall, but not in patients not taking antihypertensive medications. However, these findings must be carefully interpreted due to potential sampling bias. In addition, due to the limited specimens obtained by the needle biopsies, we could not determine the intrarenal localization of the specimens. The results of previous autopsy and biopsy studies in patients with essential hypertension suggested that the AO lesions might reflect the consequence of increased blood pressure [37, 38].
There are several limitations associated with the present study. First, the cause–effect relationships between the renal histopathological findings and the ABP values were undetermined since our study was designed as a cross-sectional study. Secondly, the ABP values might have been modified by decreased physical activity and diet with 6 g/day of sodium chloride during the hospitalization period. Future studies performed at outpatient clinics will help to clarify this issue.
In conclusion, our results suggest that the T score according to the OC is the most relevant renal histopathological parameter associated with ABP values in IgAN patients. Although the detailed mechanisms are largely undetermined at present, our results indicate the novel advantage of the T score using the OC for predicting functional abnormalities of circadian blood pressure regulation in IgAN patients.
Supplementary data
Supplementary data are available online at http://ckj.oxfordjournals.org.
Conflict of interest statement
None declared.
Supplementary Material
Acknowledgements
Portions of this study were presented at the American Society of Nephrology Kidney Week 2014, November 2014, Philadelphia, PA.
References
- 1.Kiryluk K, Novak J. The genetics and immunobiology of IgA nephropathy. J Clin Invest 2014; 124: 2325–2332 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Lee H, Kim DK, Oh K-H, et al. Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One 2012; 7: e51225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Moriyama T, Tanaka K, Iwasaki C, et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One 2014; 9: e91756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534–545 [DOI] [PubMed] [Google Scholar]
- 5.Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546–556 [DOI] [PubMed] [Google Scholar]
- 6.Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int 2014; 86: 828–836 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult Chinese patients. Am J Kidney Dis 2012; 60: 812–820 [DOI] [PubMed] [Google Scholar]
- 8.Katafuchi R, Ninomiya T, Nagata M, et al. Validation study of the Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol 2011; 6: 2806–2813 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kawamura T, Joh K, Okonogi H, et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. J Nephrol 2013; 26: 350–357 [DOI] [PubMed] [Google Scholar]
- 10.Boggia J, Silvariño R, Luzardo L, et al. Significance of white-coat and masked hypertension in chronic kidney disease and end-stage renal disease. Hypertens Res 2014; 37: 882–889 [DOI] [PubMed] [Google Scholar]
- 11.Mojón A, Ayala DE, Piñeiro L, et al. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 2013; 30: 145–158 [DOI] [PubMed] [Google Scholar]
- 12.Iimuro S, Imai E, Watanabe T, et al. Clinical correlates of ambulatory BP monitoring among patients with CKD. Clin J Am Soc Nephrol 2013; 8: 721–730 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006; 69: 1175–1180 [DOI] [PubMed] [Google Scholar]
- 14.Minutolo R, Gabbai FB, Agarwal R, et al. Assessment of achieved clinic and ambulatory blood pressure recordings and outcomes during treatment in hypertensive patients with CKD: a multicenter prospective cohort study. Am J Kidney Dis 2014; 64: 744–752 [DOI] [PubMed] [Google Scholar]
- 15.D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 2004; 24: 179–196 [DOI] [PubMed] [Google Scholar]
- 16.Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 2011; 22: 752–761 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Matsuo S, Imai E, Horio M, et al. Collaborators developing the Japanese equation for estimated GFR: revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992 [DOI] [PubMed] [Google Scholar]
- 18.Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–2219 [DOI] [PubMed] [Google Scholar]
- 19.Sato R, Joh K, Komatsuda A, et al. Validation of the Japanese histologic classification 2013 of immunoglobulin A nephropathy for prediction of long-term prognosis in a Japanese single-center cohort. Clin Exp Nephrol 2015; 19: 411–418 [DOI] [PubMed] [Google Scholar]
- 20.Kikuya M, Hansen TW, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk. Circulation 2007; 115: 2145–2152 [DOI] [PubMed] [Google Scholar]
- 21.Wu Q, Jinde K, Nishina M, et al. Analysis of prognostic predictors in idiopathic membranous nephropathy. Am J Kidney Dis 2001; 37: 380–387 [DOI] [PubMed] [Google Scholar]
- 22.Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77: 820–829 [DOI] [PubMed] [Google Scholar]
- 23.Okada T, Nagao T, Matsumoto H, et al. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrology 2012; 17: 68–75 [DOI] [PubMed] [Google Scholar]
- 24.Konishi Y, Okada N, Okamura M, et al. Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. Hypertension 2001; 38: 81–85 [DOI] [PubMed] [Google Scholar]
- 25.Mashima Y, Konta T, Kudo K, et al. Increases in urinary albumin and beta2-microglobulin are independently associated with blood pressure in the Japanese general population: the Takahata Study. Hypertens Res 2011; 34: 831–835 [DOI] [PubMed] [Google Scholar]
- 26.Johnson RJ, Herrera-Acosta J, Schreiner GF, et al. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913–923 [DOI] [PubMed] [Google Scholar]
- 27.Alvarez V, Quiroz Y, Nava M, et al. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002; 283: F1132–F1141 [DOI] [PubMed] [Google Scholar]
- 28.Vanegas V, Ferrebuz A, Quiroz Y, et al. Hypertension in page (cellophane-wrapped) kidney is due to interstitial nephritis. Kidney Int 2005; 68: 1161–1170 [DOI] [PubMed] [Google Scholar]
- 29.Zhao D, Seth DM, Navar LG. Enhanced distal nephron sodium reabsorption in chronic angiotensin II-infused mice. Hypertension 2009; 54: 120–126 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mamenko M, Zaika O, Prieto MC, et al. Chronic angiotensin II infusion drives extensive aldosterone-independent epithelial Na+ channel activation. Hypertension 2013; 62: 1111–1122 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wakui H, Tamura K, Masuda S, et al. Enhanced angiotensin receptor-associated protein in renal tubule suppresses angiotensin-dependent hypertension. Hypertension 2013; 61: 1203–1210 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ohsawa M, Tamura K, Wakui H, et al. Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension. Kidney Int 2014; 86: 570–581 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Escano CS, Armando I, Wang X, et al. Renal dopaminergic defect in C57Bl/6J mice. Am J Physiol Regul Integr Comp Physiol 2009; 297: R1660–R1669 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Desir GV. Role of renalase in the regulation of blood pressure and the renal dopamine system. Curr Opin Nephrol Hypertens 2011; 20: 31–36 [DOI] [PubMed] [Google Scholar]
- 35.Kohan DE. Role of collecting duct endothelin in control of renal function and blood pressure. Am J Physiol Regul Integr Comp Physiol 2013; 305: R659–R668 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Okonogi H, Utsunomiya Y, Miyazaki Y, et al. A predictive clinical grading system for immunoglobulin A nephropathy by combining proteinuria and estimated glomerular filtration rate. Nephron Clin Pract 2011; 118: c292–c300 [DOI] [PubMed] [Google Scholar]
- 37.Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955; 1: 33–42 [DOI] [PubMed] [Google Scholar]
- 38.Castleman B, Smithwick RH. The relation of vascular disease to the hypertensive state. Based on a study of renal biopsies from one hundred hypertensive patients. JAMA 1943; 121: 1256–1261 [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.